SPECIFIC IMMUNOTHERAPY AND CELLULAR IMMUNITY IN PATIENTS WITH CERVICAL CANCER
https://doi.org/10.15789/1563-0625-2013-1-55-60
Abstract
Cellular mechanisms are quite important immunological components of tumor surveillance, being, however, most vulnerable to influence of different adverse factors, including surgery-associated stress and ionizing radiation. Our study was aimed for assessing specific effects of immunotherapy upon indices of cellular immunity in patients with cervical cancer. Eighty-eight patients with cervical cancer (clinical stage I-IIA, Т1аN0M0-T2aN0M0), who underwent appropriate surgery (for IA stage), or a combined treatment, including surgery gamma-ray teletherapy (IB, IIA stages) are under study. The patients were distributed in two groups, depending on the therapy applied. Group 1 included patients subjected to surgical treatment plus and radiation therapy, Group 2 included those patients who were treated according to this protocol, with addition of a specific immunotherapy. Contents of T cells and various CD subpopulations of T-lymphocytes were identified by immunofluorescence techniques. Among patients with cervical cancer at clinical stages IA, IB, IIA, a reliable decrease in cellular immunity indices was registered, both after surgery, and during combined treatment. Introduction of specific immunotherapy to the conventional treatment schedule was associated with increase of cellular immune indices, and, in first line, the antineoplastic mechanisms (e.g., NK’s and NKT cell contents). One should point to a relatively low efficiency of this immunotherapy in combined treatment of patients with cervical cancer at IIA stage.
About the Authors
D. K. Kenbaeva
Городской онкологический диспансер, г. Астана
Kazakhstan
Kazakhstan
A. F. Lazarev
Алтайский филиал государственного учреждения Российский онкологический центр им. Н.Н. Блохина РАМН, г. Барнаул
Russian Federation
Russian Federation
Z. A. Manambaeva
Государственный медицинский университет, г. Семей
Kazakhstan
Kazakhstan
References
1. Лыков А.П., Басс А.А., Морозов Д.В., Абрамов В.В., Козлов В.А. Аденокарцинома желудка: клинико-иммунологические особенности // Вопросы онкологии. – 2003. – № 1. – C. 41-43.
2. Camus M., Galon J. Memory T-cell responses and survival in human cancer: remember to stay alive // Adv. Exp. Med. Biol. – 2010. – Vol. 684. – P. 166-177.
3. Маринова-Мутафчиева Л.П., Чакалова Г.Б., Горанов И.Т. Супрессия клеточного иммунитета у больного с карциномой in situ и микроинвазивным раком шейки матки // Вопросы онкологии. – 1997. – Т. 37, № 4. – C. 454-456.
4. Osada J., Kamocki Z., Rusak M., Dabrowska M., Kedra B. The effect of surgical and nutritional treatment on activation parameters of peripheral blood T lymphocytes in stomach cancer patients in postoperative period // Pol Merkur Lekarski. – 2008. – Vol. 24 (141). – P. 231-236.
5. Гранов А.М., Винокуров В.Л. Лучевая терапия в онкогинекологии и онкоурологии. – СПб.: Фолиант, 2002. – 352 с.
6. Футисова Л.И. Фагоцитарная активность свободных легочных макрофагов после гамма-облучения // Медицинская радиология. – 1997. – № 5. – С. 74-76.
7. Phillips A.W., Fenwick J.D., Mallick U.K., Perros P. The impact of clinical guidelines on surgical management in patients with breast cancer // Clinice Oncology (R Coll Radiol). – 2003. – Vol. 15, N 8. – P. 485-489.
8. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment // Nat Rev Cancer. – 2012. – Vol. 12 (4). – P. 237-251.
9. Танатова З.А. Особенности и повышение эффективности лечения злокачественных новообразований репродуктивной системы женщин в регионе Семипалатинского ядерного полигона: Автореф. дис. ... д.м.н. – Астана, 2007. – 257 с.
Review
For citations:
Kenbaeva D.K., Lazarev A.F., Manambaeva Z.A. SPECIFIC IMMUNOTHERAPY AND CELLULAR IMMUNITY IN PATIENTS WITH CERVICAL CANCER. Medical Immunology (Russia). 2013;15(1):55-60. (In Russ.) https://doi.org/10.15789/1563-0625-2013-1-55-60
Views:
950
Email this article 